Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Prednisone · Rayos, NSC-10023

Small molecule · developed by Horizon

Approved FDA, Jul 2012

AMGN Developer

1 Registered trials

What is Prednisone?

Prednisone is a glucocorticoid that acts as an agonist of the glucocorticoid receptor, suppressing immune responses and reducing inflammation. It is studied in primary immune thrombocytopenia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Rayos, NSC-10023, Predniso(lo)ne
Drug type: Small molecule
Therapy area: Immunology
Developer: Horizon (AMGN)
FDA status: Approved as Rayos (July 26, 2012), NDA202020
UNII: VB0R961HZT

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07700238	Phase 3	Primary Immune Thrombocytopenia	Recruiting	AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Immune Thrombocytopenia

More from Horizon

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Follow AMGN, the company behind Prednisone

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z